Beyond Cabergoline: Could Vitamin B6 Offer a New Approach to Canine Pseudopregnancy?

Pseudopregnancy, or pseudocyesis, is one of the most common reproductive disorders encountered in intact female dogs. Although often regarded as a physiological phenomenon of diestrus, clinically affected bitches may develop pronounced mammary enlargement, milk secretion, nesting behavior, anorexia, restlessness, and maternal instincts that can significantly concern owners and impact animal welfare^1,2. 

The condition develops in non-pregnant bitches during diestrus and mimics many of the physiological changes observed during late pregnancy and the postpartum period. Recurrent episodes are common, with susceptible dogs often showing signs after successive estrous cycles¹. Beyond the immediate clinical presentation, pseudopregnancy has also been associated with an increased risk of mammary pathology, including mammary neoplasia². 

Why Prolactin Matters 

The hormonal basis of pseudopregnancy revolves around the interaction between progesterone and prolactin. 

Following the luteal phase, a decline in progesterone concentration triggers an increase in prolactin secretion. This prolactin surge is considered a key driver of mammary development, lactation, and many of the behavioral changes observed in pseudopregnant bitches³. 

Although studies have not consistently demonstrated a direct relationship between circulating prolactin concentrations and the severity of clinical signs, the effectiveness of prolactin-inhibiting drugs such as cabergoline and metergoline strongly supports prolactin's central role in the syndrome's pathogenesis¹. 

The Challenges with Traditional Therapy 

For many veterinarians, cabergoline remains the preferred treatment option because it effectively suppresses prolactin release and rapidly improves clinical signs. 

However, treatment options may be limited in some settings. Metergoline, another prolactin inhibitor, has been associated with adverse effects including gastrointestinal disturbances, aggressiveness, excessive vocalization, and hyperexcitability. Additionally, prolonged treatment can increase costs for owners, particularly in recurrent cases¹. 

This has prompted interest in alternative therapies that target prolactin secretion while offering improved affordability and tolerability. 

Vitamin B6: An Unexpected Candidate 

Recent research has highlighted pyridoxine hydrochloride (Vitamin B6) as a potential therapeutic option for canine pseudopregnancy. 

Vitamin B6 plays a critical role as a coenzyme in the conversion of L-dopa to dopamine. Because dopamine is the primary inhibitor of prolactin secretion, increasing dopamine availability may indirectly suppress prolactin release and reduce pseudopregnancy signs⁴. 

How Does It Compare with Cabergoline? 

A study evaluating pseudopregnant bitches found that pyridoxine hydrochloride administered at 50 mg/kg produced reductions in serum prolactin concentrations comparable to those achieved with cabergoline at 5 µg/kg¹. 

Importantly, both treatments were associated with improvement in clinical signs, supporting the theory that prolactin suppression remains a key therapeutic target in pseudopregnancy management. 

One of the most interesting findings was that pyridoxine achieved these effects without the undesirable side effects commonly reported with ergot-derived medications. Furthermore, treatment costs were substantially lower than cabergoline therapy, making it an attractive option in cost-sensitive clinical situations. 

Why Clinical Signs Don't Always Match Prolactin Levels 

An intriguing observation from the study was that some dogs with lower prolactin concentrations displayed clinical signs similar to those with higher concentrations. 

This suggests that circulating prolactin concentration alone may not fully explain disease severity. 

Researchers believe that different molecular forms of canine prolactin may contribute to these variations. Similar to humans, dogs appear to possess multiple prolactin isoforms that differ in biological activity and receptor affinity. Consequently, two dogs with similar serum prolactin concentrations may exhibit markedly different clinical presentations¹. 

This may explain why prolactin measurements do not always correlate with the intensity of clinical signs observed in practice. 

Beyond Lactation: Effects on the Corpus Luteum 

The study also provided insight into prolactin's luteotropic role in dogs. 

Corpora lutea were identified in some untreated animals, reinforcing the importance of prolactin in maintaining luteal function and progesterone production during diestrus¹. 

Because both cabergoline and pyridoxine reduce prolactin concentrations, investigators proposed that these treatments may accelerate luteal regression. This raises interesting questions regarding their potential influence on progesterone secretion and reproductive management, warranting further investigation. 

Practical Takeaways for Veterinarians 

For practitioners managing pseudopregnancy, several key points emerge: 

• Prolactin remains a central therapeutic target. 

• Cabergoline continues to be an effective first-line treatment. 

• Vitamin B6 (pyridoxine hydrochloride) shows promise as a low-cost alternative capable of reducing prolactin concentrations and improving clinical signs. 

• Clinical severity may not always reflect serum prolactin levels because of differences in prolactin bioactivity. 

• Additional research is needed before pyridoxine can be routinely recommended as a standard treatment protocol. 

Conclusion 

Canine pseudopregnancy remains a hormonally driven condition in which prolactin plays a pivotal role. While cabergoline continues to be the benchmark therapy, emerging evidence suggests that pyridoxine hydrochloride may offer a safe, affordable, and effective alternative for reducing prolactin concentrations and controlling lactation-associated signs. As interest grows in practical and cost-effective reproductive therapies, Vitamin B6 may become an important addition to the veterinarian's therapeutic toolbox, particularly in cases where conventional treatment is inaccessible or poorly tolerated. 

References

1. Silva MC, Guedes PE, Silva FL, Snoeck PP. Use of pyridoxine hydrochloride in the interruption of lactation in female dogs with pseudopregnancy. Animal Reproduction. 2021 Apr 12;18:e20200062. https://www.scielo.br/j/ar/a/6WtY56svdm49g4QMB6jxCNQ/?format=html&lang=en

2. Root AL, Parkin TD, Hutchison P, Warnes C, Yam PS. Canine pseudopregnancy: an evaluation of prevalence and current treatment protocols in the UK. BMC veterinary research. 2018 May 24;14(1):170. https://link.springer.com/content/pdf/10.1186/s12917-018-1493-1.pdf

3. Singh LK, Bhimte A, Pipelu W, Mishra GK, Patra MK. Canine pseudopregnancy and its treatment strategies. depression. 2018;17(19):20. https://www.researchgate.net/profile/Laishram-Singh/publication/325646239_

4. McRae G, Runcan E, Johnson A. Estrous cycle manipulation in dogs. Clinical Theriogenology. 2025 Feb 14;17:82-6. https://clinicaltheriogenology.net/index.php/CT/article/download/11647/18904